MSTN and sarcopenia: Due to the central role of MSTN in controlling muscle growth, this myokine has been associated with the loss of muscle mass in sarcopenia, muscular dystrophy, and cachexia and is currently being investigated as a possible therapeutic target in these pathological conditions [33,34].